Evoke Pharma (EVOK) has released an update.
Evoke Pharma, Inc. is on notice from Nasdaq for its stock price dropping below the $1.00 minimum requirement, risking delisting from The Nasdaq Capital Market. The company has until August 19, 2024, to regain compliance, which requires maintaining a bid price of $1.00 or more for ten consecutive business days. While currently maintaining its listing, Evoke Pharma is exploring options to meet Nasdaq’s criteria and may consider a reverse stock split as a remedy. If unable to comply by the deadline, the company could be granted an additional period to rectify the issue or face delisting, with the opportunity to appeal the decision.
For further insights into EVOK stock, check out TipRanks’ Stock Analysis page.
